Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials-Reference-Cited by-同舟云学术

Efficacy and safety of tanezumab administered as a fixed dosing regimen in patients with knee or hip osteoarthritis: a meta-analysis of randomized controlled phase III trials

Published:2020-11-06 Issue:6 Volume:40 Page:2155-2165
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Fan Zheng-rui,Ma Jian-xiong,Wang Ying,Chen Heng-ting,Lang Shuang,Ma Xin-long

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-020-05488-4.pdf

Reference28 articles.

1. Hunter DJ, Bierma-Zeinstra S (2019) Osteoarthritis. Lancet 393(10182):1745–1759. https://doi.org/10.1016/S0140-6736(19)30417-9

2. Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P (2008) OARSI recommendations for the management of hip and knee osteoarthritis, part II: OARSI evidence-based, expert consensus guidelines. Osteoarthr Cartil 16(2):137–162. https://doi.org/10.1016/j.joca.2007.12.013

3. Wolfe F, Zhao S, Lane N (2000) Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 43(2):378–385. https://doi.org/10.1002/1529-0131(200002)43:2<378::AID-ANR18>3.0.CO;2-2

4. Altman RD (2009) Practical considerations for the pharmacologic management of osteoarthritis. Am J Manag Care 15(8 Suppl):S236–S243

5. Balanescu AR, Feist E, Wolfram G, Davignon I, Smith MD, Brown MT, West CR (2014) Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann Rheum Dis 73(9):1665–1672. https://doi.org/10.1136/annrheumdis-2012-203164

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging injectable therapies for osteoarthritis;Expert Opinion on Emerging Drugs;2022-07-03

2. Analgesic effects of nerve growth factor‐directed monoclonal antibody on diabetic neuralgia in an animal model;FEBS Open Bio;2022-05-03

3. Osteoarthritis year in review 2021: epidemiology & therapy;Osteoarthritis and Cartilage;2022-02

4. Tanezumab for the treatment of osteoarthritis pain;Drugs of Today;2022

5. Efficacy and safety of biologic agents for the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials;Therapeutic Advances in Musculoskeletal Disease;2022-01